Comparative biochemical and pharmacological investigations of various newly developed opioid receptor ligands by Szűcs, Edina
Summery of Ph.D. thesis 
Comparative biochemical and pharmacological investigations of 
various newly developed opioid receptor ligands 
Edina Szűcs 
Supervisor: 
Sándor Benyhe, PhD, DSc 
 
Institute of Biochemistry, 
Biological Research Centre, Szeged 
Doctoral School of Theoretical Medicine, 
Faculty of Medicine, University of Szeged 
SZEGED 
2020
 1  
INTRODUCTION 
Opioid system and pain 
 Morphine is a prototype opioid agonist binding to MOR and is still the most frequently 
used drug in pain medication. Beside pain relief and analgesia, it has serious side effects 
including decreased respiratory effort, low blood pressure and it also has a high potential for 
addiction and abuse. Therefore, it is very important to find new ligands with higher affinity, 
selectivity and stability to get more effective drugs to decrease the side effects. 
 An opioid epidemic is the overuse or misuse of addictive opioid drugs. It has significant 
medical, social and economic consequences, including overdose deaths. The proclamation of 
“The Opioid Crisis” by the U.S. Surgeon General began with the over-prescription of opioids in 
the 1990s, which are the most prescribed class of medications in the United States. Opioids 
administrated postoperatively or for pain management are one of the leading causes of opioid 
misuse, where approximately 6% of people continued opioid use after surgery or trauma. In 2017 
fentanyl was the most common synthetic opioid, it was also listed by the World Health 
Organization as an essential drug in the form of fentanyl patches for cancer pain. Yet in 2016, 
the illegally used fentanyl and its analogues caused the most common overdose deaths in the 
United States, accounting for more than 20,000, around half of opioid-related deaths. 
 The three primary symptoms (which may not always be present together) for opioid 
toxicity are:  respiratory depression, generally accompanied by depressed consciousness and 
miosis. Naloxone therapy is the standard treatment for opioid toxicity. Opioids that require larger 
doses of naloxone: codeine, methadone, diphenoxylate, propoxyphene, pentazocine, butorphanol, 
nalbuphine. Naloxone can precipitate withdrawal symptoms including: anxiety, irritability, and 
restlessness; gooseflesh; hot and cold sweats; muscle-, bone- and joint aches; tremor; nausea, 
vomitting and diarrhea; increased resting pulse rate. 
 Opioids combined with non-opioid drugs are another way to treat moderate to severe pain 
decreasing the risk of tolerance and dependence (e.g. Percodan: oxycodone/aspirin, Percocet: 
oxycodone/paracetamol, Vicodin: hydrocodone/paracetamol, Vicoprofen: 
hydrocodone/ibuprofen). 
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KYNA and pain 
 Different NMDA receptor sites were examined in the rat model of formalin-induced 
facial pain. The results showed that the nociceptive behavioural responses were effectively 
reduced by the NR2 subunits, which means that these subunits have importance in inflammatory 
pain diseases. Intracisternal KYNA attenuates formalin-induced nociception in animals together 
with antagonist activity at the glycine binding site of NMDA receptor, which is associated with 
analgesic properties in rats. At the peripheral sites, KYNA decreases the nociceptive behaviour 
in the tail flick- and hot plate tests. Administration of kyn and probenecid together with KYNA 
analogues inhibits NMDA receptors in animal models of trigeminal activation and sensitization. 
Noteworthy, KYNA and its analogues are able to act on second‐order neurons, decreasing 
mechanical allodynia and pain sensitivity in different animal pain models. 
 The activation of GPR35 by KYNA, leads to hyperpolarization in the cell, which 
decreases glutamate and pro-inflammatory substance release from the glial and immune cells, 
another way of the analgesic effect of KYNA in inflammatory models. The agonist KYNA and 
zaprinast could inhibit the AC of DRG in an inflammatory pain model through GPR35. 
Probenecid injection amplified the effects of the two agonists, zaprinast was more effective in 
lower concentration compared to KYNA. These results suggest that the GPR35 could be a 
promising and novel pharmacological target for the inflammatory pain reduction. 
 Both kynurenine and KYNA binds to HACR3, which is then able to promote the 
generation of immune-suppressive T cells that support cancer development. The question is 
whether the KYNA-induced activation of HCAR3 and the effects, such as elevated 
kynurenine/KYNA levels can increase the risk of developing malignancies. Or the anti-
inflammatory actions of kynurenines due to a controlled activation of HACR3 may be used for 
the treatment of different immune disorders. This can be another approach for the management 
of cancer related pain. 
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Bentley analogues 
 Natural morphine alkaloids (e.g. morphine, codeine, thebaine, neopine, oripavine) can be 
converted into a variety of pharmacologically more advantageous compounds, such as the so 
called nal-compounds (naloxone, naltrexone, nalbuphine) and the ring-C bridged derivatives 
(6,14-ethenomorphinans or Bentley-compounds, e.g. etorphine (9), buprenorphine, 
diprenorphine). In this study nine previously synthesized orvinol and thevinol-type MOR-
selective ligands were examined (compounds 1e, 1f, 2a, 2b, 2d, 4, 5, 7, 8 (3-methoxyetorphine)). 
6-O-desmethyl-dihydroethorphine (2c) is a new compound synthesized for this study. 
 A number of structure-activity relationship studies dealing with thevinol and orvinol 
derivatives are available, but the biochemical and pharmacological properties of our target 
compounds have not been reported except for 8. The aim of present study was to compare the 
receptor binding properties and the MOR, DOR and KOR selectivity of some Bentley 
compounds in rat and guinea pig brain membrane preparations. The ligands were also 
investigated in [
35S]GTPγS functional binding assays to examine G-protein activation via opioid 
receptors. The effect of the investigated derivatives was observed in vivo nociceptive tests. 
 The presence or absence of specific functional groups in the orvinol and thevinol 
derivatives can not be straightforwardly related to their pharmacological profiles. As an example, 
the 17-N-substituent serves as an acknowledged pharmacological switch between agonists and 
antagonists being methyl or cyclopropylmethyl (CPM), respectively. However, it is highly 
ambiguous within this class of opioids, regarding that 17-N-CPM derivative can be full agonist 
as well which may be a consequence of the bigger size of these opiates resulting in a more 
complex interaction pattern with the receptor. According to this, it seems plausible to investigate 
the interacting residues or atoms of the receptor leading to the specific response, i.e. 
pharmacological feature. 
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Oligopeptides 
 Considering the presence of kyn residue in natural peptide sequences and the important 
role exerted by both kynurenines in the CNS, the aim was to investigate the biological 
consequences of the insertion of these residues in opioid pharmacophore sequences. Kyn could 
be used in place of phenylalanine (Phe), considering its aromatic side chain, whereas KYNA 
could be used as a C‐terminus to mimic an additional aromatic residue. The synthesis and 
biological screening of six novel kynurenines containing peptides were performed, aiming to 
investigate the modifications imposed by the presence of kyn and KYNA on the biological 
properties of known endogenous and synthetic opioid peptides in vivo and in vitro. Peptide KA1 
retains the DAMGO primary sequence, but the OH terminal group is esterified by KYNA. 
Peptides K2 and K3 are EM‐2 analogues in which the Phe residues in positions 3 and 4 have 
been replaced with kyn and kyn C‐terminal amides, respectively. Peptides K4–K6 are 
enkephalin‐like peptides containing kyn in position 5, bearing as C‐terminal the methyl ester, 
acid, and amide group, respectively. The novel chemical entities were prepared following 
solution phase peptide synthesis and were obtained as TFA salts in good overall yields and 
excellent purities. 
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AIMS OF THE STUDY 
 Opioid ligands still play inevitably role in the MOR-mediated central and peripheral 
antinociception, although their use can be very dangerous. The aim of this study is to find new 
ligands, which have higher maximal efficacy at lower concentration than the frequently used 
morphine to decrease the risk of side effects (such as dependence and tolerance) of analgesic 
drugs. For this purpose, 9 known and 1 new Bentley analogues, and 6 newly synthesized 
oligopeptides (DAMGO, EM-2 and enkephalin-like peptides containing kynurenines) are 
described in this thesis to find out after comparison which direction of synthesis is more 
expedient. 
The objectives of the study presented in the thesis were the following: 
 To measure the binding affinity of the 10 Bentley compounds towards MOR, DOR and 
KOR and the 6 new oligopeptides towards MOR, DOR, KOR and NMDA receptor in 
competition binding assay in rat and guinea pig brain membranes. 
 To examine G-protein activation and opioid receptor mediation of the ligands in 
functional [
35S]GTPγS binding. 
 To analyse the antiallodynic effects of the Bentley analogues and the oligopeptides in 
vivo test using inflammation models. 
 To compare the final results of biochemical and pharmacological experiments of the 
examined opioid ligands. 
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METHODS 
Competition binding experiments 
 The radioligand competition binding experiment is a type of binding assay, where 
radioactive ligand is applied (in most cases tritium labelled) in fixed concentrations in the 
presence of increasing concentrations of an unlabelled ligand. If the unlabelled ligand has 
specificity towards the receptor as the radioligand, The value of binding affinity (Ki) can be 
received about the applied unlabelled ligand. 
Functional [
35S]GTPγS binding experiments 
 In the [
35S]GTPγS binding assays the ligand mediated G-protein activation is monitored, 
namely the GDP → GTP exchange of Gα, in the presence of an agonist ligand in increasing 
concentration. The nucleotide exchange is detected by a non-hydrolysable, radioactive GTP 
analogue called [
35S]GTPγS. Two values can be obtained from the experiments: Emax value 
(maximum efficacy) and logEC50 value (ligand potency) describe the agonist activity of the 
ligands. 
In vivo nociceptive studies 
Bentley analogues were examined using male Wistar rats. Osteoarthritis was induced by 
injecting MIA (1 mg/30 mL) into the tibiotarsal joint of the right hind leg on two consecutive 
days. 
Oligopeptides were examined using CD-1 male mice. In the formalin test, the injection of a 
dilute solution of formalin (1%, 20 μL/paw) into the dorsal surface of the mouse hind paw 
evoked biphasic nociceptive behavioural responses. 
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SUMMARY OF THE RESULTS 
 Bentley analogues 
In vitro competition binding experiments all derivatives showed low subnanomolar affinity to 
MOR. For DOR the ligands showed comparable binding affinities than the selective DOR 
agonist Ile
5,6
-deltorphin II peptide ligand except 8 (Ki > 3000 nM). In the KOR binding assays 
the analogues still displayed nanomolar affinities. 
In G-protein activity measurements compound 1f, 2a, 2b had antagonistic; 1e, 2c, 8 had partial 
agonistic and 2d, 4, 5, 7 had full agonistic effects. 
Ligands were examined in G-protein activation tests in rat brain membrane, the selectivity could 
not be observed as the receptor selective antagonists such as Cyp, NTI, nor-BNI and the selective 
agonists such as DAMGO, Ile
5,6
-deltorphine II, U-69,593 are not able to inhibit the effects of the 
extremely potent Bentley analogues. 
In vivo tests in osteoarthritis inflammation model the thevinol derivatives showed a significant 
antiallodynic effect, while orvinol derivatives, except for 2c, did not display this effect. 
 Oligopeptides 
In competition binding assays the KYNA‐containing peptide, KA1 bound selectively to the 
MOR with a low Ki value and high selectivity ratio, the other oligopeptides also showed 
selectivity to MOR, except K3, which bound to MOR and DOR with similar affinity. 
In the G-protein activation tests the EM-2 containing compounds, K2 and K3 stimulated G-
protein with low efficacy, compound KA1, K4, K5 behaved as full agonists, while K6 had 
efficacy and potency higher than those of the reference compound DAMGO. 
In functional binding assays all oligopeptides were inhibited by Cyp (MOR) and NTI (DOR) in 
rat brain membrane. In guinea pig brain membrane K4 and K6 stimulated G-protein, the efficacy 
of K4 was inhibited by nor-BNI, while the effect of K6 was not. 
K6 exhibited a strong antinociceptive effect in formalin test. 
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